The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: A brief report

Afsaneh Shirani  
*Washington University School of Medicine in St. Louis*

Anne H. Cross  
*Washington University School of Medicine in St. Louis*

Robert T. Naismith  
*Washington University School of Medicine in St. Louis*

Multiple Sclerosis Partners Advancing Technology and Health Solutions Investigators#

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**

[https://digitalcommons.wustl.edu/open_access_pubs/7564](https://digitalcommons.wustl.edu/open_access_pubs/7564)
Short report

The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report

Afsaneh Shirani, Anne H Cross and Robert T Naismith; for the Multiple Sclerosis Partners Advancing Technology and Health Solutions Investigators

Abstract

A relationship between handedness and clinicodemographic profiles of people with multiple sclerosis was sought using data from the Multiple Sclerosis Partners Advancing Technology Health Solutions network of 10 multiple sclerosis centers in the USA and Europe. Handedness data were available for 8888 multiple sclerosis patients, of which 917 (10.3%) were left-handed. Clinicodemographic profiles of right versus left-handed multiple sclerosis patients were similar except for a slightly increased proportion of men who were left-handed, and slightly reduced performance on the manual dexterity test using the non-dominant hand in left-handed patients. We found no evidence to suggest a prognostic implication of handedness in multiple sclerosis.

Keywords: Multiple sclerosis, handedness, epidemiology

Date received: 22 December 2018; Revised received 23 January 2019; accepted: 28 January 2019

Introduction

The relationship between handedness and autoimmune diseases such as multiple sclerosis (MS) is debated.1–3 A previous study of female US nurses suggested a modest increase in the risk of MS among left-handed women.1 It has also been proposed that HLA-alleles associated with an increased risk of MS and circulating autoantibodies may be more common among left-handed individuals.4

Approximately 11% of the general population is left-handed.5 Few population-based studies have examined the relationship between handedness and demographic or clinical characteristics of people with MS (PwMS). Multiple Sclerosis Partners Advancing Technology Health Solutions (MS PATHS)6 is a collaborative network including 10 MS centers in the USA and Europe and provides access to a large cohort of PwMS. In this study, we investigated the association between handedness and clinicodemographic profile of enrollees in MS PATHS.

Methods

This cross-sectional study utilized data from the MS PATHS network. MS PATHS is a collaborative network sponsored by Biogen which includes seven centers in the USA and three centers in Europe, and is based on the concept of a learning health system.6 During routine clinic visits, people with MS undergo the multiple sclerosis performance test (MSPT) which is an iPad-based assessment including structured patient history, electronic adaptations of the multiple sclerosis functional composite, and the neuro-quality of life (neuro-QoL) outcome instrument.7

We queried MS PATHS for PwMS recruited from the inception of the database (11/2015) through 3/2018. Requested variables included sex, age at MS onset and diagnosis, MS subtype, level of education, handedness, patient determined disease steps (PDDS) and relevant components of MSPT assessment including manual dexterity test (MDT), walking speed time (WST), contrast sensitivity test.
investigators within MS PATHS contributed to the design and implementation of MS PATHS and/or provided data but did not participate in analysis or writing of this report.

writing of this report.

participate in analysis or provided data but did not design and implementation

PATHS contributed to the investigators within MS

of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

Results
A total of 9618 PwMS were identified (73.2% women). Handedness data were available for 8888 patients, of which 917 (10.3%) were left-handed. Table 1 shows the demographic and clinical profiles of the patients. Among women with MS, 9.5% were left-handed whereas 12.4% of men with MS were left-handed. Women comprised a greater proportion of right-handed than of left-handed PwMS (74.0% vs. 67.8%, P < 0.001). Overall, right and left-handed patients had a similar age at MS diagnosis, PDDS, and MS subtype. Approximately 65% of PwMS had relapsing–remitting MS in both handedness groups. The mean time to complete MDT with the left hand was not associated with handedness. The mean time to complete MDT with the right hand was slightly longer in left-handed compared to right-handed PwMS (28.9±8.3 vs. 27.6±7.6 seconds, P <0.001). Results for WST, CST, PST, and neuro-QoL upper extremity and cognitive domain scores were similar between right and left-handed PwMS. Stratification by sex did not change our findings.

To examine if any major underlying upper extremity dysfunction might have impacted our findings (by affecting patient-reported handedness), we performed a sensitivity analysis by including a subset of patients whose MDT performance values were in the best performance quartile (<23 seconds) thus having minimal functional impairment of upper extremities. In this subset (n=1393, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 20.0±1.7 seconds for right-handed patients and 20.0±1.8 in left-handed patients. Time to complete MDT with the non-dominant hand was 20.8±1.6 in right-handed patients, and 20.0±1.8 in left-handed patients. These results did not change our interpretation of the findings.

We also investigated if right-handed and left-handed patients might have been differentially impacted when MDT performance is more severely impaired. To examine this, we performed another sensitivity analysis by including a subset of patients whose MDT performance values were in the worst performance quartile (>32 seconds). In this subset (n=1184, 10.1% left-handed), the mean±SD time to complete MDT with the dominant hand was 40.6±6.4 seconds for right-handed patients and 40.3±6.2 for left-handed patients. Time to complete MDT with the non-dominant hand was 38.9±6.2 in right-handed patients, and 40.0±6.8 in left-handed patients. These results did not change our interpretation of the findings.

Discussion
In this large cross-sectional study using data from MS PATHS, 10.3% of PwMS were left-handed, close to the estimated 11% prevalence of left-handedness or mixed-handedness in the US general population.5 The higher prevalence of left-handedness among male PwMS compared to women (12.4% vs. 9.5%) in our study is consistent with the general population. A meta-analysis found a higher prevalence of left-handedness in men in the general population, with an estimated male to female odds ratio of 1.23 (95% confidence interval (CI) 1.19–1.27).8

A previous cohort study using data from the Nurses’ Health Study reported a 62% increased risk of MS among women who were naturally left-handed as compared to those who were right-handed (relative risk=1.62, 95% CI 1.04–2.53)1 and suggested that prenatal exposure to sex hormones may possibly play a role in MS risk.9,10 That study included only women, and was not designed to examine the clinical characteristics of incident MS cases. We compared the clinical profiles of right versus left-handed PwMS to seek any evidence to support that left-handed MS patients may have an earlier MS onset or altered clinical severity. No strong evidence to suggest this was found. However, we found a slightly longer mean time to complete MDT with the non-dominant hand (right hand) in left-handed PwMS. The mean time to complete MDT with the left hand was similar between right-handed and left-handed MS patients. The mean age at MS onset in left-handed PwMS was minimally higher than right-handed
PwMS. The implications of these subtle differences are unclear.

We were unable to examine the relationship between handedness and MS onset symptom laterality because MS PATHS does not capture the details of onset symptoms. Future studies should examine this potential relationship, given that the brain networks responsible for controlling the less dexterous non-dominant hand may have a lower reserve capacity, and therefore impairments of the fine motor control of the non-dominant hand may be discernable at an earlier stage of MS.

Overall, we found no evidence to suggest a prognostic implication of handedness in MS. Our study also encourages using MS PATHS for conducting clinical research in MS.

Table 1. Demographic and clinical profile of right-handed versus left-handed patients with MS (n = 8888).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Right-handed (n = 7971)</th>
<th>Left-handed (n = 917)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, a n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>5898 (74.0)</td>
<td>622 (67.8)</td>
<td>&lt;0.001b</td>
</tr>
<tr>
<td>Men</td>
<td>2068 (25.9)</td>
<td>294 (32.1)</td>
<td></td>
</tr>
<tr>
<td>Age at MS symptom onset, c years, mean ± SD</td>
<td>32.3 ± 11.2</td>
<td>32.6 ± 11.8</td>
<td>0.008d</td>
</tr>
<tr>
<td>Age at MS diagnosis, years, mean ± SD</td>
<td>35.2 ± 11.0</td>
<td>35.6 ± 11.5</td>
<td>0.066d</td>
</tr>
<tr>
<td>Education, f years, median (IQR)</td>
<td>14 (12–16)</td>
<td>14 (12–16)</td>
<td>0.068g</td>
</tr>
<tr>
<td>Disease subtype, h n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsing–remitting</td>
<td>4764 (64.3)</td>
<td>549 (65.5)</td>
<td>0.20b</td>
</tr>
<tr>
<td>Secondary progressive</td>
<td>1381 (18.6)</td>
<td>164 (19.6)</td>
<td></td>
</tr>
<tr>
<td>Primary progressive</td>
<td>595 (8.0)</td>
<td>50 (6.0)</td>
<td></td>
</tr>
<tr>
<td>Progressive relapsing</td>
<td>665 (9.0)</td>
<td>75 (8.9)</td>
<td></td>
</tr>
<tr>
<td>Patient determined disease steps, i median (IQR)</td>
<td>1 (0–3)</td>
<td>1 (0–3)</td>
<td>0.279g</td>
</tr>
<tr>
<td>Manual dexterity test for right hand, j seconds, mean ± SD</td>
<td>27.6 ± 7.6</td>
<td>28.9 ± 8.3</td>
<td>&lt;0.001d</td>
</tr>
<tr>
<td>Manual dexterity test for left hand, k seconds, mean ± SD</td>
<td>29.0 ± 7.7</td>
<td>28.7 ± 8.0</td>
<td>0.333d</td>
</tr>
<tr>
<td>Neuro-QoLt upper extremity function t-score, m mean ± SD</td>
<td>45.5 ± 9.5</td>
<td>45.1 ± 9.5</td>
<td>0.95d</td>
</tr>
<tr>
<td>Walking speed time, n seconds, mean ± SD</td>
<td>7.4 ± 4.9</td>
<td>7.7 ± 5.2</td>
<td>0.187d</td>
</tr>
<tr>
<td>Contrast sensitivity test o at high (100%) contrast, p mean ± SD</td>
<td>57.0 ± 6.3</td>
<td>56.6 ± 6.1</td>
<td>0.248d</td>
</tr>
<tr>
<td>Contrast sensitivity test o at low (2.5%) contrast, p mean ± SD</td>
<td>33.7 ± 13.0</td>
<td>32.9 ± 13.5</td>
<td>0.174d</td>
</tr>
<tr>
<td>Processing speed test, q seconds, mean ± SD</td>
<td>46.9 ± 12.9</td>
<td>46.6 ± 12.9</td>
<td>0.613d</td>
</tr>
<tr>
<td>Neuro-QoLt cognitive function t-score, m mean ± SD</td>
<td>46.2 ± 9.1</td>
<td>45.6 ± 8.9</td>
<td>0.91d</td>
</tr>
</tbody>
</table>

aData for sex were missing for six patients.

bChi-square test
cData for age at MS symptoms onset were missing for 414 patients.
dStudent’s t-test
eDate for age at MS diagnosis were missing for 538 patients.
fData for education were missing for 310 patients.
gMann–Whitney U test.
hData for MS disease subtype were missing for 645 patients.
iData for patient determined disease steps were missing for 75 patients.
jData for manual dexterity test for the right hand were missing for 890 patients.
kData for manual dexterity test for the left hand were missing for 922 patients.
lScores for neuro-quality of life (Neuro-QoL) are reported using a t distribution, with the mean of the reference population set to 50 and the standard deviation set to 10 units. Lower t scores indicate less of the concept being measured. For instance, a t score of 45 for upper extremity function, is 0.5 standard deviation worse than the average.
mData for Neuro-QoL were missing for 2083 patients.
nData for walking speed time were missing for 1068 patients.
oThe contrast sensitivity testing is based on the Sloan low contrast letter acuity test and evaluates binocular acuity with a maximum number correct of 60 at high (100%) and low (2.5%) contrast.
pData for contrast sensitivity test were missing for 3814 patients.
qData for processing speed test were missing for 625 patients.
Acknowledgements

We would like to express our thanks to the MS PATHS clinical research coordinators at Washington University in St. Louis including Courtney Dula, MS, Dana Perantie, MPH, and Shannon Sides, BA, as well as all the other MS PATHS research coordinators at other sites. We would also like to thank Dana Perantie, MPH for her help with IRB preparation and submission.

Conflict of Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AS is funded through a clinician scientist development award from the National Multiple Sclerosis Society (USA), and a clinical research training scholarship from the American Academy of Neurology. AHC has been a paid consultant for Biogen, Celgene, EMD-Serono, Genzyme, Genentech, and Novartis. AHC was funded in part by the Manny and Rosalyn Rosenthal – Dr John L Trotter MS Center Chair in Neuroimmunology of Barnes-Jewish Hospital Foundation. RTN has received honoraria for consulting for Alkermes, Biogen, Celgene, Novartis; and for speaking for EMD Serono, Genzyme, Genentech, and Novartis.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) database was funded by Biogen.

ORCID iD

Afsaneh Shirani http://orcid.org/0000-0002-8866-6426

References